Patent Evaluation: Bridging Antibody Fusion Constructs

Summary

Novelty: A novel bridging antibody is disclosed. It appears to bind to a surface antigen on an effector cell and a surface protein on a target cell; it is claimed to be suitable for the treatment of cancers and viral infections.

Biology: Significant killing of target cells was said to occur at low effector-to-target ratios in the presence of the construct. Results are presented in a graph which shows killing to increase directly with the concentration of bridging antibody.

Chemistry: The sequence of 1742 amino-acids is given.